Neil Korman
University Hospitals Cleveland Medical Center · Case Western Reserve University School of Medicine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Neil Korman as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 04:13 UTC. Open this list on ClinicalTrials.gov
- N/ANCT06399432 · Mediterranean Diet vs no Dietary Intervention for Improving Signs and Symptoms of Psoriasis in Patients Treated With Anti-IL-17 or Anti-IL-23 InhibitorsUniversity Hospitals Cleveland Medical Center · recruiting · Psoriasis · principal investigator
- Early Ph1NCT04410237 · Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery SystemUniversity Hospitals Cleveland Medical Center · completed · Psoriasis · principal investigator
- N/ANCT03820934 · FibroScan ® Study: Assessing Liver Fibrosis in Patients Using Methotrexate for PsoriasisUniversity Hospitals Cleveland Medical Center · withdrawn · Psoriasis · principal investigator
- Ph2NCT03442088 · Monocyte Biomarkers in Moderate to Severe Plaque Psoriasis Subjects Treated With ApremilastUniversity Hospitals Cleveland Medical Center · completed · Plaque Psoriasis · principal investigator
- N/ANCT02330380 · Comparative Effectiveness of Psoriasis Treatments on Systemic InflammationUniversity Hospitals Cleveland Medical Center · completed · Psoriasis, Inflammation · principal investigator
- Ph2NCT00869089 · Safety and Efficacy of CC-10004 for Prurigo NodularisUniversity Hospitals Cleveland Medical Center · completed · Prurigo Nodularis · principal investigator
- Ph2NCT00606749 · Use of KC706 for the Treatment of Pemphigus VulgarisKemia, Inc · completed · Pemphigus Vulgaris · principal investigator
- Ph2NCT00429533 · Efficacy of Dapsone as a Steroid Sparing Agent in Pemphigus VulgarisJacobus Pharmaceutical · terminated · Pemphigus Vulgaris · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 04:13 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Translational Research CoreP30AR039750 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1994 to 2010 · $147,330 awarded in 2010Same name and institution; not confirmed by an ID
- EPIDERMAL BULLOUS PEMPHIGOID ANTIGENR29AR041008 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1994 to 1998 · $114,853 awarded in 1998Same name and institution; not confirmed by an ID
- CHARACTERIZATION OF EPIDERMAL BULLOUS PEMPHIGOID ANTIGENR55AR041008 · NIAMS · CASE WESTERN RESERVE UNIVERSITY · fiscal years 1991 · $100,000 awarded in 1991Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 04:13 UTC. The ranking covers the 200 most relevant of 28 PubMed records, and a shared surname and initials can bring in a namesake. All 28 on PubMed
- Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.N Engl J Med · 2016623 citationsRCR 26.5
- 507 citationsRCR 21.3
- Topical capsaicin treatment of chronic postherpetic neuralgia.J Am Acad Dermatol · 1989209 citationsRCR 10.1
- 149 citationsRCR 6.1
- Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials.Arch Dermatol · 2005131 citationsRCR 3.4
- Efficacy and safety of tacrolimus ointment treatment for up to 4 years in patients with atopic dermatitis.J Am Acad Dermatol · 200595 citationsRCR 3.3
- The impact of tacrolimus ointment on health-related quality of life of adult and pediatric patients with atopic dermatitis.J Am Acad Dermatol · 200191 citationsRCR 3.6
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials.J Am Acad Dermatol · 202490 citationsRCR 17.1
- Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).Br J Dermatol · 201883 citationsRCR 4.5
- A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders.Clin Cancer Res · 200969 citationsRCR 1.7